Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Invested Capital (2022 - 2025)

Historic Invested Capital for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $772.4 million.

  • NewAmsterdam Pharma's Invested Capital rose 9419.38% to $772.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $772.4 million, marking a year-over-year increase of 9419.38%. This contributed to the annual value of $795.0 million for FY2024, which is 16415.32% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Invested Capital stood at $772.4 million, which was up 9419.38% from $799.4 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Invested Capital's 5-year high stood at $800.9 million during Q1 2025, with a 5-year trough of $8414.1 in Q2 2023.
  • For the 4-year period, NewAmsterdam Pharma's Invested Capital averaged around $495.9 million, with its median value being $427.9 million (2024).
  • As far as peak fluctuations go, NewAmsterdam Pharma's Invested Capital tumbled by 3960.1% in 2023, and later surged by 488435731.76% in 2024.
  • Quarter analysis of 4 years shows NewAmsterdam Pharma's Invested Capital stood at $498.3 million in 2022, then plummeted by 39.6% to $301.0 million in 2023, then soared by 164.15% to $795.0 million in 2024, then dropped by 2.84% to $772.4 million in 2025.
  • Its Invested Capital stands at $772.4 million for Q3 2025, versus $799.4 million for Q2 2025 and $800.9 million for Q1 2025.